Intellia Therapeutics Inc
North American company
Times are shown in GMT-5, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Intellia Therapeutics Inc is a genome editing company. It is focused on developing proprietary, potentially curative CRISPR/Cas9-based therapeutics. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema, and ex vivo programs which include Acute Myeloid Leukemia.Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
Latest NTLA News
Currently there are no news & analysis articles for this instrument. Visit our news hub for the latest investment news from ii and Alliance News